Home About Us LungVantage Active Targeting Research Leadership News Contact Viomics - Early Detection of Cancer

LungVantage

LungVantage

Lung Cancer kills more people in the U.S. than any other cancer. In fact, it kills as many people as breast, colorectal, pancreatic and prostate cancers combined. However, if caught early, chances of surviving lung cancer for more than 5 years increase from 14% to 85%.

Despite years of medical advances, lung cancer is the only major cancer that cannot be routinely detected in early stages. Major advances allow dramatic increases in survivability for other cancers by early detection, including breast (mammogram), prostate (PSA) and colorectal (colonoscopy). Despite smokers and others being at risk and a prime screening target for lung cancer, no effective screening test exists.

Viomics has developed the LungVantage test that finally gives patients an advantage over lung cancer by detecting it early. By measuring three blood borne markers in our CLIA laboratory, we can detect lung cancer with over 90% accuracy. This is a five fold decrease in false positive rate and four fold decrease in false negative rate when compared to CT scans. Our test has been shown to detect all stages of cancer effectively, including the earliest stages where it is still treatable. The LungVantage assay has been validated as a fully automated and highly multiplexed assay with an average turnaround time of 4 hours.

Contact us now to participate in our prospective clinical trial or to discuss licensing opportunities.

   

©Copyright 2012 Viomics Inc. All rights reserved.